CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026 ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.89, moving 1.21% from the previous trading session.

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.39, moving -1.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%.

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...

Scientists edited the promoter of the rice gene OsGTL1 to lower stomatal density, raising instantaneous water use efficiency ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

Researchers at Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) found that removing a protein called SMCHD1 lifted the genetic "brake," allowing healthy but dormant genes to ...

Prime Medicine has dosed the first participant in an in vivo prime-editing trial for Wilson disease. The administration is a ...

H.C. Wainwright reiterated a USD 80.00 target for CRISPR Therapeutics on October 9, 2026. The USD 80.00 target stood 60.39 ...